US FDA Modifies Fact Sheet of Johnson & Johnson to Include Rare Bleeding Disorder

The Food and Drug Administration (FDA) of the United States has been modifying the fact sheet for the novel corona virus vaccine of Johnson & Johnson for the purpose of including a rare risk of the immune thrombocytopenia, which is a rare bleeding disorder.

The US FDA said that, the reports of the adverse events has been followed by the use of the novel corona virus vaccine of Johnson and Johnson under the authorization of the emergency use that has been suggesting an increased risk of the immune thrombocytopenia during the time period of 42 days followed by the corona virus vaccination in the United States.

The US FDA also said that, the symptoms have also been including the tiny blood spots and easy bruising under the excessive, unusual or skin bleeding, and the modification of the fact sheet of the corona virus vaccine of Johnson and Johnson following similar moves for the corona virus vaccine by the several other regulators, which is also including that of the regulators of the European Medicines Agency in the month of October 2021.

Both the novel corona virus vaccines developed by Johnson and Johnson and AstraZeneca, that are based on a similar platform have previously been associated with another very rare mixture of the low counts of the platelets and clotting of the blood, which are known as thrombosis along with the thrombocytopenia syndrome.